Irinotecan hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for irinotecan hydrochloride and what is the scope of patent protection?
Irinotecan hydrochloride
is the generic ingredient in three branded drugs marketed by Ipsen, Pfizer Inc, Accord Hlthcare, Actavis Totowa, Chartwell Rx, Cipla Ltd, Emcure Pharms Ltd, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hengrui Pharma, Hikma Farmaceutica, Hisun Pharm Hangzhou, Hospira, Intas Pharms Usa, Novast Labs, Pliva Lachema, Qilu Pharm Hainan, Sandoz, Shilpa, Sun Pharma Global, Teva Pharms Usa, West-ward Pharms Int, and Zennova, and is included in twenty-eight NDAs. There are seventeen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Irinotecan hydrochloride has one hundred and twenty-three patent family members in twenty-eight countries.
There are thirty drug master file entries for irinotecan hydrochloride. Sixteen suppliers are listed for this compound.
Summary for irinotecan hydrochloride
International Patents: | 123 |
US Patents: | 17 |
Tradenames: | 3 |
Applicants: | 25 |
NDAs: | 28 |
Drug Master File Entries: | 30 |
Finished Product Suppliers / Packagers: | 16 |
Raw Ingredient (Bulk) Api Vendors: | 97 |
Clinical Trials: | 1,505 |
Patent Applications: | 6,975 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in irinotecan hydrochloride? | irinotecan hydrochloride excipients list |
DailyMed Link: | irinotecan hydrochloride at DailyMed |
Recent Clinical Trials for irinotecan hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
ECOG-ACRIN Cancer Research Group | Phase 3 |
Mirati Therapeutics | Phase 1 |
MEI Pharma, Inc. | Phase 1 |
Pharmacology for irinotecan hydrochloride
Drug Class | Topoisomerase Inhibitor |
Mechanism of Action | Topoisomerase Inhibitors |
Paragraph IV (Patent) Challenges for IRINOTECAN HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CAMPTOSAR | Injection | irinotecan hydrochloride | 20 mg/mL, 2 mL and 5 mL vials | 020571 | 1 | 2004-07-26 |
US Patents and Regulatory Information for irinotecan hydrochloride
Expired US Patents for irinotecan hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer Inc | CAMPTOSAR | irinotecan hydrochloride | INJECTABLE;INJECTION | 020571-001 | Jun 14, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Pfizer Inc | CAMPTOSAR | irinotecan hydrochloride | INJECTABLE;INJECTION | 020571-002 | Jun 14, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Pfizer Inc | CAMPTOSAR | irinotecan hydrochloride | INJECTABLE;INJECTION | 020571-002 | Jun 14, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Pfizer Inc | CAMPTOSAR | irinotecan hydrochloride | INJECTABLE;INJECTION | 020571-001 | Jun 14, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Pfizer Inc | CAMPTOSAR | irinotecan hydrochloride | INJECTABLE;INJECTION | 020571-002 | Jun 14, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Pfizer Inc | CAMPTOSAR | irinotecan hydrochloride | INJECTABLE;INJECTION | 020571-001 | Jun 14, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for irinotecan hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 108366965 | 稳定喜树碱药物组合物 (Stabilizing camptothecin pharmaceutical compositions) | ⤷ Try a Trial |
Canada | 2821167 | LIPOSOMES POUR L'ADMINISTRATION DE DROGUES CONTENANT DES POLYOLS ANIONIQUES OU DES SUCRES ANIONIQUES (DRUG DELIVERY LIPOSOMES CONTAINING ANIONIC POLYOLS OR ANIONIC SUGARS) | ⤷ Try a Trial |
Russian Federation | 2663450 | СПОСОБЫ ЛЕЧЕНИЯ РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ С ПРИМЕНЕНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЛИПОСОМНЫЙ ИРИНОТЕКАН (METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPY COMPRISING LIPOSOMAL IRINOTECAN) | ⤷ Try a Trial |
South Korea | 101997206 | ⤷ Try a Trial | |
Japan | 5665950 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2013188586 | ⤷ Try a Trial | |
Canada | 2928387 | LIPOSOMES POUR L'ADMINISTRATION DE DROGUES CONTENANT DES POLYOLS ANIONIQUES OU DES SUCRES ANIONIQUES (DRUG DELIVERY LIPOSOMES CONTAINING ANIONIC POLYOLS OR ANIONIC SUGARS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for irinotecan hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1746976 | 132017000076571 | Italy | ⤷ Try a Trial | PRODUCT NAME: SALE SUCROSOFATO DI IRINOTECAN, COME IL SALE SUCROSOFATO DI IRINOTECAN IN UN LIPOSOMA PEGILATO(ONIVYDE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1130, 20161018 |
0137145 | SPC/GB97/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
1746976 | 1790033-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT.; REG. NO/DATE: EU/1/16/1130 20161008 |
1746976 | 17C1027 | France | ⤷ Try a Trial | PRODUCT NAME: SEL DE SUCROSOFATE D'IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
1746976 | SPC/GB17/043 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REGISTERED: UK EU/1/16/1130 20161018 |
1746976 | 2017C/027 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
1746976 | CR 2017 00030 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REG. NO/DATE: EU/1/16/1130 20161018 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.